Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate

Immix Biopharma reported a Q4 loss of $(0.28) per share, missing the analyst consensus estimate of $(0.16) by 75%. This represents a 75% increase in losses compared to $(0.16) per share from the same period last year.